This article covers Imiquimod, available as a generic medication and marketed under brand names such as Aldara and Zyclara. Imiquimod is classified in the Skin Care therapeutic category and is supplied as a 5 % cream in a tube.
Imiquimod is a prescription-only (Rx) topical agent approved by health authorities, including the Hong Kong Department of Health, for the treatment of certain skin lesions. It works by stimulating the body's own immune response to destroy abnormal skin cells.
Imiquimod is a synthetic immune response modifier. It binds to toll-like receptor 7 (TLR7) on immune cells in the skin, which triggers a cascade of signals that:
The drug is applied topically, so systemic absorption is minimal. The immune activation typically begins within a few hours, peaks after several days, and the local skin reaction may persist for up to two weeks after the last application.
Imiquimod is approved in Hong Kong for the following indications:
These uses are supported by regulatory review and clinical trial data demonstrating effective clearance of lesions with an acceptable safety profile.
There are no widely endorsed off-label applications for Imiquimod that meet the strict evidence criteria required for inclusion. Studies investigating its use in conditions such as lentigo maligna, cutaneous melanoma in situ, or recalcitrant warts remain limited and are not approved by regulatory agencies.
Off-label use requires medical supervision and individualized risk assessment.
These reactions are usually dose-dependent and indicate that the medication is working.
If any of these occur, stop the medication and seek medical attention promptly.
No major cytochrome-P450 interactions have been identified, as systemic absorption is minimal.
Each application should use one fingertip-size amount of the 5 % cream per lesion, spread evenly, and left on the skin for 6-10 hours (or as directed). After the prescribed exposure time, wash the treated area with mild soap and water, then gently pat dry.
If a dose is missed, apply it as soon as remembered unless it is less than 12 hours before the next scheduled dose. Do not double the dose.
Signs of overdose are uncommon but may include extensive skin inflammation, flu-like symptoms, or systemic rash. Seek urgent medical care; treatment is supportive (e.g., topical steroids, antihistamines).
For actinic keratosis and sBCC, abrupt cessation after the prescribed course is acceptable. For genital warts, a short break (2-3 days) may be taken if severe irritation occurs, then resume at the same frequency.
This article provides educational information about Imiquimod and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Apply the cream to clean, dry skin. Moisture can dilute the medication and reduce its ability to penetrate the skin, potentially decreasing efficacy.
The local inflammatory response may persist for up to two weeks after the final application as the skin continues to heal and clear residual abnormal cells.
Most Imiquimod tubes are made of recyclable plastic. Check local recycling guidelines; you may need to separate the cap from the tube before placing it in the appropriate recycling bin.
Yes, but apply sunscreen after washing off the cream and allowing the skin to dry. Choose a non-chemical (physical) sunscreen to minimize further irritation.
A rash limited to untreated skin may indicate an allergic reaction or secondary infection. Stop the medication and seek medical evaluation promptly.
Because systemic absorption is minimal, Imiquimod does not typically alter routine laboratory values. However, severe skin inflammation could theoretically affect inflammatory markers.
Temporary changes such as redness, swelling, and crusting are expected. These usually resolve without scarring, but patients should discuss any concerns about hyperpigmentation with their clinician.
Yes. Imiquimod is a prescription medication; keep it in its original packaging with the prescription label visible. Follow airline liquid restrictions if the cream exceeds 100 ml, but most tubes are under this limit.
Cryotherapy physically destroys warts using liquid nitrogen, while Imiquimod stimulates an immune response to clear viral lesions. Clinical studies show comparable clearance rates, but Imiquimod may be preferred for patients who wish to avoid painful freezing.
